Ammonia oxidizing bacteria for treatment of rosacea

Patent metadata

Field	Value
Publication number	US-10131871-B2
Application number	US-201815958803-A
Country	US
Kind code	B2
Filing date	Apr 20, 2018
Priority date	Apr 15, 2014
Publication date	Nov 20, 2018
Grant date	Nov 20, 2018

Abstract

A method for treating a skin disorder, e.g., acne, e.g. acne vulgaris, in a subject is provided. The method comprises administering, e.g., applying, e.g., topically administering, ammonia oxidizing bacteria, e.g., a preparation comprising ammonia oxidizing bacteria, to a surface of the subject. Preparations comprising ammonia oxidizing bacteria for treating such skin disorder, e.g., acne, e.g. acne vulgaris in a subject are also provided.

First claim

The invention claimed is:

1. A method of treating rosacea in a subject, comprising:
administering, as a spray, aerosol or mist, a preparation comprising live ammonia oxidizing bacteria, to the skin of the subject, in an amount effective to treat rosacea.

2. The method of claim 1 , wherein a peptide associated with rosacea is altered.

3. The method of claim 1 , wherein administering the preparation reduces inflammation.

4. The method of claim 1 , wherein administering provides for treatment or improvement of one or more of erythema, edema, scaling, stinging, burning, and itching.

5. The method of claim 1 , wherein administering provides for treatment or improvement of one or more of oily appearance, pore appearance, radiance, blotchiness, skin tone evenness, visual smoothness, and tactile smoothness.

6. The method of claim 1 , further comprising determining whether the subject is in need of treating rosacea or reducing the severity or frequency of at least one symptom of rosacea.

7. The method of claim 1 , wherein the preparation of ammonia oxidizing bacteria comprises a suspension of the ammonia oxidizing bacteria in a buffer solution.

8. The method of claim 7 , wherein the buffer solution is an aqueous buffer solution consisting essentially of disodium phosphate and magnesium chloride.

9. The method of claim 1 , wherein the preparation is applied to any one or more of a face, neck, scalp, head, shoulder, arm, leg, underarm, torso, feet, knee, ankle, and buttocks of the subject.

10. The method of claim 9 , wherein the preparation is applied to the face of the subject.

11. The method of claim 1 , wherein the preparation further comprises an excipient.

12. The method of claim 1 , wherein the ammonia oxidizing bacteria is selected from the group consisting of Nitrosomonas, Nitrosococcus, Nitrosospira, Nitrosocystis, Nitrosolobus, Nitrosovibrio , and combinations thereof.

13. The method of claim 12 , wherein the ammonia oxidizing bacteria is Nitrosomonas eutropha ( N. eutropha ).

14. The method of claim 13 , wherein the ammonia oxidizing bacteria is N. eutropha D23, having ATCC accession number PTA-121157.

15. The method of claim 1 , wherein the preparation is applied for about 7 to about 28 days.

16. The method of claim 1 , wherein a rosacea treatment selected from the group of:
an antibiotic, sandalwood oil, clonidine, a beta-blocker, an antihistamine, mirtazapine, methylsulfonylmethane, silymarin, laser therapy, light therapy, and combinations thereof is further administered to the subject.

17. The method of claim 1 , wherein the preparation comprises viable ammonia oxidizing bacteria capable of converting ammonia or ammonium to nitrite at a rate of at least about 50 micromoles nitrite per minute.

Assignees

• Aobiome Llc

Inventors

• Whitlock David R
• Jamas Spiros
• Weiss Larry

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title